Zentalis-supplied Phase 2 pancreatic trial of ZN-c3 plus gemcitabine ends early on toxicity
A Brandon Huffman-led Phase 2 study combining Zentalis's ZN-c3 with gemcitabine in advanced pancreatic cancer was terminated after hitting its dose-limiting toxicity threshold, with results posted October 27, 2026.
This week's single item concerns a terminated Phase 2 trial that tested a Zentalis-associated WEE1 inhibitor in combination with standard chemotherapy for pancreatic cancer.
- The trial, "Phase 2 Single Arm Trial Testing the ZN-c3 WEE1 Inhibitor in Combination With Gemcitabine in Second-Line Advanced Pancreatic Adenocarcinoma" (NCT06015659), is sponsored by Brandon Huffman, MD, and was terminated because the study stopped early due to reaching the minimum number of DLTs required for halting the study due to toxicity.1 Zentalis is named as a collaborator, described as "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc,"1 and the record states that Zentalis is supplying the study drug, ZN-c3.1 The study was designed to enroll about 34 people1 but actual enrollment reached 12 participants (actual)1. Primary completion was listed as 2025-08-06 (actual)1, with results first posted on 2026-10-27 (actual)1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.